Monopar Therapeutics (MNPR) stock, explained like you're 5

Is Monopar Therapeutics a small, medium or large cap company?

No. Monopar Therapeutics is a small cap stock, not a large cap. Its market cap, which is the total value of all its shares, is about 530 million dollars.

Here is how you can tell. Multiply the share price by the number of shares to get the market cap, then compare it to the usual sizes. Micro cap is under 300 million dollars, small cap is 300 million to 2 billion, mid cap is 2 to 10 billion, large cap is 10 billion and up, and mega cap is over 200 billion. Market caps move every day with the share price, so treat the number as a recent snapshot.

How Monopar Therapeutics makes money

• Selling medicines, medical devices or healthcare services.
• Insurance premiums or hospital and clinic fees.
• Research and licensing deals.

What moves MNPR stock

• Results from clinical trials and approvals from regulators.
• Drug prices, insurance rules and government policy.
• Patents running out and new competing treatments.

In the news lately

• This Monopar Therapeutics Insider Reduced Their Stake By 37% (Simply Wall Street)
• Technical Reactions to MNPR Trends in Macro Strategies (Stock Traders Daily)
• Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade (Yahoo Finance)
• After a $0.005 per share option exercise, Monopar Therapeutics (MNPR) director sells 8,400 shares. (Stock Titan)
• Form 4 Monopar Therapeutics Inc: Andrew Cittadine (COO) For: 30 September (Investing.com Nigeria)

Key terms to know before you follow MNPR

• Market cap
• P/E ratio
• EPS (earnings per share)
• Earnings report
• Volatility